ABSTRACT
WHO details that obesity has reached epidemic proportions worldwide and each year at least 2.8 million people die from obesity or overweight. Disease compromises the different body systems with a life expectancy of between 5 and 20 years approximately. Growing data set suggests that end results related to the disease caused by the SARS-CoV-2 virus are worse in patients who are obese and that a significant proportion of those in intensive care are overweight or obese. The present study aims to systematically review the available evidence regarding obesity, its characteristics, current drug therapy and its future prospects. The information was obtained using scientific databases. The literature review highlights the advances in the development of combined pharmacological therapies for the treatment of obesity beyond interventions in diet or lifestyle. Experimental combination drug therapy includes phentarmine/topiramate and naltrexone/bupropion combinations as well as incretin hormone inhibitors, showing drug combinations such as glucagon-like peptide-1 (GLP-1) with glucose-dependent receptor agonist drugs. insulin-tropic peptides (GIP).